“It’s a memorable day for all of us. Covid-19 has impacted all of our lives in so many ways, and the hope for an exit strategy has rested on a safe and effective vaccine. To achieve this within this time frame is remarkable and the researchers should be applauded.
“Although the development of this vaccine has been rapid, it is important to note that it will still have undergone all rigorous safety tests, and the validity of the efficacy data will have been carefully assessed by the MHRA. ”
While Dr John Tregoning, a reader of respiratory infections at Imperial Oil, said: “This is great news and remarkable progress as the first cases date back less than a year. It shows the progress that can be made through science and innovation.
Dr Michael Head, senior researcher in global health at the University of Southampton, said regulators were “clearly pleased” with the efficacy and safety of the vaccine.
“The Pfizer vaccine requires storage at around -70 ° C, which will pose significant logistical challenges for all countries that choose to use it,” said Dr Head.
“It’s not insurmountable, but certainly difficult. Other vaccines, such as the Oxford candidate AstraZeneca, require storage at much lower temperatures and will be easier to transport. But, for now, this is great news to wake up to. ”